Emergent BioSolutions Inc. (NYSE:EBS) Shares Acquired by Covestor Ltd

Covestor Ltd boosted its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 5,458.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,946 shares of the biopharmaceutical company’s stock after purchasing an additional 2,893 shares during the quarter. Covestor Ltd’s holdings in Emergent BioSolutions were worth $28,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in EBS. SBI Securities Co. Ltd. purchased a new position in shares of Emergent BioSolutions during the 4th quarter worth about $63,000. E Fund Management Co. Ltd. acquired a new position in Emergent BioSolutions during the fourth quarter worth approximately $98,000. Stifel Financial Corp acquired a new position in Emergent BioSolutions during the third quarter worth approximately $96,000. Cornercap Investment Counsel Inc. purchased a new position in Emergent BioSolutions during the fourth quarter worth approximately $115,000. Finally, LPL Financial LLC boosted its holdings in shares of Emergent BioSolutions by 34.5% in the 4th quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 3,875 shares during the last quarter. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Emergent BioSolutions

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at $589,413. The trade was a 25.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.20% of the stock is owned by corporate insiders.

Emergent BioSolutions Stock Performance

NYSE:EBS opened at $4.62 on Wednesday. The firm’s fifty day simple moving average is $6.29 and its 200 day simple moving average is $8.40. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a twelve month low of $1.82 and a twelve month high of $15.10. The firm has a market capitalization of $251.20 million, a price-to-earnings ratio of -1.13 and a beta of 2.14.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.40. The company had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the previous year, the firm posted ($0.77) earnings per share. As a group, equities research analysts expect that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions declared that its Board of Directors has approved a share repurchase plan on Monday, March 31st that allows the company to repurchase $50.00 million in shares. This repurchase authorization allows the biopharmaceutical company to reacquire up to 19% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on EBS shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, April 1st. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.